ECSP18002725A - Agentes, usos y métodos para el tratamiento - Google Patents

Agentes, usos y métodos para el tratamiento

Info

Publication number
ECSP18002725A
ECSP18002725A ECIEPI20182725A ECPI201802725A ECSP18002725A EC SP18002725 A ECSP18002725 A EC SP18002725A EC IEPI20182725 A ECIEPI20182725 A EC IEPI20182725A EC PI201802725 A ECPI201802725 A EC PI201802725A EC SP18002725 A ECSP18002725 A EC SP18002725A
Authority
EC
Ecuador
Prior art keywords
treatment
agents
methods
antibodies
pgrn
Prior art date
Application number
ECIEPI20182725A
Other languages
English (en)
Spanish (es)
Inventor
Den Brink Edward Van
Rønn Lars Christian Biilmann
Jong Rob De
Jan Egebjerg
Arnout Gerritsen
Søren Christensen
Jeffrey B Stavenhagen
Ibrahim John Malik
Paul Parren
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP18002725A publication Critical patent/ECSP18002725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ECIEPI20182725A 2015-07-13 2018-01-12 Agentes, usos y métodos para el tratamiento ECSP18002725A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
ECSP18002725A true ECSP18002725A (es) 2018-03-31

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20182725A ECSP18002725A (es) 2015-07-13 2018-01-12 Agentes, usos y métodos para el tratamiento

Country Status (35)

Country Link
US (6) US10428147B2 (OSRAM)
EP (1) EP3322726B1 (OSRAM)
JP (2) JP6979397B2 (OSRAM)
KR (1) KR102778576B1 (OSRAM)
CN (3) CN114478775A (OSRAM)
AR (1) AR105335A1 (OSRAM)
AU (1) AU2016292980B2 (OSRAM)
BR (1) BR112018000771A2 (OSRAM)
CA (1) CA2989739A1 (OSRAM)
CL (2) CL2018000092A1 (OSRAM)
CO (1) CO2017012988A2 (OSRAM)
CR (1) CR20180002A (OSRAM)
DO (1) DOP2018000014A (OSRAM)
EA (1) EA201890038A1 (OSRAM)
EC (1) ECSP18002725A (OSRAM)
ES (1) ES3024469T3 (OSRAM)
GB (1) GB201512215D0 (OSRAM)
HR (1) HRP20250602T1 (OSRAM)
HU (1) HUE071424T2 (OSRAM)
IL (1) IL256503B (OSRAM)
JO (1) JO3710B1 (OSRAM)
MA (1) MA42440B1 (OSRAM)
MX (1) MX2018000506A (OSRAM)
NI (1) NI201800007A (OSRAM)
PE (1) PE20181014A1 (OSRAM)
PH (1) PH12018500100A1 (OSRAM)
PL (1) PL3322726T3 (OSRAM)
RS (1) RS66856B1 (OSRAM)
RU (1) RU2735639C2 (OSRAM)
SV (1) SV2018005613A (OSRAM)
TN (1) TN2017000534A1 (OSRAM)
TW (1) TWI760305B (OSRAM)
UA (1) UA125136C2 (OSRAM)
WO (1) WO2017009327A1 (OSRAM)
ZA (1) ZA201708613B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CA3060547A1 (en) * 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
CN114981297A (zh) * 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
US20230235048A1 (en) * 2020-06-24 2023-07-27 Andriani IOANNOU Antibodies recognizing sortilin
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
AU6375000A (en) 1999-07-29 2001-02-19 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
HUE048781T2 (hu) 2006-12-21 2020-08-28 H Lundbeck As Proneurotrofinok aktivitásának modulációja
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
EP2293667A4 (en) 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CA3060547A1 (en) 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN114478775A (zh) 2022-05-13
EP3322726B1 (en) 2025-03-12
JO3710B1 (ar) 2021-01-31
EA201890038A1 (ru) 2018-06-29
WO2017009327A1 (en) 2017-01-19
US12331123B2 (en) 2025-06-17
CN114478774A (zh) 2022-05-13
UA125136C2 (uk) 2022-01-19
EP3322726A1 (en) 2018-05-23
TN2017000534A1 (en) 2019-04-12
ES3024469T3 (en) 2025-06-04
HRP20250602T1 (hr) 2025-07-18
ZA201708613B (en) 2021-03-31
US20170267761A1 (en) 2017-09-21
PE20181014A1 (es) 2018-06-26
US20230159643A1 (en) 2023-05-25
KR20180030045A (ko) 2018-03-21
CO2017012988A2 (es) 2018-05-21
DOP2018000014A (es) 2018-04-15
IL256503B (en) 2022-02-01
RU2018100824A (ru) 2019-08-13
MA42440B1 (fr) 2025-05-30
AU2016292980B2 (en) 2022-10-06
TW201702273A (zh) 2017-01-16
SV2018005613A (es) 2018-02-23
AR105335A1 (es) 2017-09-27
US11548950B2 (en) 2023-01-10
EP3322726C0 (en) 2025-03-12
US10428147B2 (en) 2019-10-01
PH12018500100A1 (en) 2018-07-30
BR112018000771A2 (pt) 2018-09-25
CL2020002468A1 (es) 2021-01-29
US20250277040A1 (en) 2025-09-04
IL256503A (en) 2018-02-28
JP2022003058A (ja) 2022-01-11
JP2018529635A (ja) 2018-10-11
CN107849135A (zh) 2018-03-27
US20210269524A1 (en) 2021-09-02
TWI760305B (zh) 2022-04-11
US10479835B2 (en) 2019-11-19
JP6979397B2 (ja) 2021-12-15
US10889650B2 (en) 2021-01-12
GB201512215D0 (en) 2015-08-19
CL2018000092A1 (es) 2018-07-06
PL3322726T3 (pl) 2025-06-23
AU2016292980A1 (en) 2018-01-18
CA2989739A1 (en) 2017-01-19
US20180305455A1 (en) 2018-10-25
HUE071424T2 (hu) 2025-08-28
US20200190188A1 (en) 2020-06-18
RU2735639C2 (ru) 2020-11-05
RS66856B1 (sr) 2025-06-30
MX2018000506A (es) 2018-05-11
NI201800007A (es) 2018-10-18
MA42440A (fr) 2018-05-23
RU2018100824A3 (OSRAM) 2020-01-17
KR102778576B1 (ko) 2025-03-07
CR20180002A (es) 2018-04-09
HK1254356A1 (en) 2019-07-19

Similar Documents

Publication Publication Date Title
ECSP18002725A (es) Agentes, usos y métodos para el tratamiento
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
PH12016502167A1 (en) Hdl theraphy markers
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX389911B (es) Anticuerpos anti-transtiretina
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX394170B (es) Anticuerpos anti-transtiretina
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
ECSP20002935A (es) Agentes, usos y métodos para el tratamiento
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
BR112017025264A2 (pt) tratamento de prurido
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX2018002020A (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
EA201991471A1 (ru) Способы введения гепсидина
EA201990694A1 (ru) Композиции для лечения деменции